GLSI · Greenwich LifeSciences, Inc. · Executive Compensation
$18.60
-0.40 (-2.08%)
At close · Sep 21
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has prepared its financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”View the 10-Q filed Aug 11, 2026
Market Cap
$269.93M
Shares
14.68M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Snehal Patel | Chief Executive Officer | $6,241,685 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Snehal Patel | Chief Executive Officer | $2,750,028 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Snehal Patel | Chief Executive Officer | $2,252,042 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Snehal Patel | CEO | $1,416,589 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Snehal Patel | CEO | $999,071 |